24 results
8-K
EX-10.1
IMUX
Immunic Inc
5 Jan 24
Immunic, Inc. Announces Private Placement of up to $240 Million
6:41am
authority, including without limitation all foreign, federal, state and local laws relating to environmental protection, occupational health and safety
8-K
EX-99.1
IMUX
Immunic Inc
4 May 23
Other Events
6:49am
Ability of IMU-856 to Renew Gut Wall and Restore Gut Health –
– No Safety or Tolerability Issues Detected –
– Conference Call and Webcast to be Held
8-K
EX-10.1
IMUX
Immunic Inc
11 Oct 22
Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing
8:30am
, including without limitation all foreign, federal, state and local laws relating to environmental protection, occupational health and safety, product
8-K
EX-10.1
IMUX
Immunic Inc
2 May 22
Entry into a Material Definitive Agreement
8:06am
(including pursuant to the Occupational Health and Safety Act) relating to the protection of human health and safety the workplace (“Occupational Laws
8-K
EX-10.1
mnqj3lk2npu62q
4 Jan 21
Entry into a Material Definitive Agreement
6:03am
8-K
EX-10.1
p4c4q3ukne ci5y
20 Oct 20
EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy
7:19am
8-K
EX-10.2
oqoeif7 f1fxhkhxr8
12 Jun 20
Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
4:05pm
8-K
EX-10.2
qsp450ajdoy6r29a33
27 Apr 20
Immunic, Inc. Announces Pricing of $15 Million Financing
5:00pm
8-K
EX-10.1
5x3bh lh9vm8
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
8-K
pbfjhq 0jb
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
424B3
iq07qwx45e
19 Feb 19
Prospectus supplement
5:03pm
S-4/A
r9p gk29rd2g
14 Feb 19
Registration of securities issued in business combination transactions (amended)
9:02am
S-4
734rj fbze8
4 Feb 19
Registration of securities issued in business combination transactions
5:58pm
8-K
EX-2.1
65ck17 v5i5
7 Jan 19
Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company
6:07am
425
EX-2.1
31e63
7 Jan 19
Business combination disclosure
6:05am